Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been assigned a $83.00 target price by stock analysts at Oppenheimer Holdings, Inc. in a research note issued to investors on Friday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer Holdings, Inc.’s price objective would indicate a potential upside of 39.19% from the stock’s current price.

A number of other equities research analysts have also issued reports on AGIO. Janney Montgomery Scott reissued a “hold” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, August 1st. Leerink Swann raised Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $50.00 to $80.00 in a research report on Wednesday, August 2nd. Canaccord Genuity set a $90.00 target price on Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 2nd. SunTrust Banks, Inc. reissued a “buy” rating and issued a $80.00 target price (up previously from $68.00) on shares of Agios Pharmaceuticals in a research report on Tuesday, August 8th. Finally, BidaskClub lowered Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Agios Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $75.70.

Shares of Agios Pharmaceuticals (AGIO) traded up $0.56 during trading on Friday, reaching $59.63. The company had a trading volume of 469,700 shares, compared to its average volume of 528,150. Agios Pharmaceuticals has a 1-year low of $39.24 and a 1-year high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The business had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. During the same quarter last year, the firm earned ($1.63) EPS. Agios Pharmaceuticals’s revenue for the quarter was up 26.4% compared to the same quarter last year. equities analysts expect that Agios Pharmaceuticals will post -6.59 earnings per share for the current year.

WARNING: “Agios Pharmaceuticals, Inc. (AGIO) Given a $83.00 Price Target by Oppenheimer Holdings, Inc. Analysts” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/11/17/agios-pharmaceuticals-inc-agio-given-a-83-00-price-target-by-oppenheimer-holdings-inc-analysts.html.

In other news, insider Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $61.99, for a total transaction of $133,030.54. Following the completion of the transaction, the insider now directly owns 8,410 shares in the company, valued at approximately $521,335.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $60.88, for a total value of $243,520.00. Following the transaction, the director now owns 82,394 shares of the company’s stock, valued at $5,016,146.72. The disclosure for this sale can be found here. Insiders have sold a total of 182,908 shares of company stock worth $12,391,239 in the last ninety days. Insiders own 10.55% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of AGIO. QS Investors LLC bought a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $144,000. Cubist Systematic Strategies LLC boosted its stake in shares of Agios Pharmaceuticals by 1,041.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 3,123 shares during the period. Aperio Group LLC bought a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $206,000. Teacher Retirement System of Texas bought a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth approximately $225,000. Finally, S&CO Inc. bought a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth approximately $227,000. Institutional investors own 93.16% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.